血管紧张素受体阻滞剂治疗covid-19:实用、适应性、多中心、3期随机对照试验
CLARITY为实用、适应性、多中心3期随机对照试验,在印度和澳大利亚17家医院纳入既往未用血管紧张素受体阻滞剂、实验室确诊SARS-CoV-2感染且住院治疗的成人患者。393例随机至血管紧张素受体阻滞剂(其中388例(98.7%)为替米沙坦40 mg/天)口服28天,394例至对照组。第14天改良WHO临床进展量表评分中位数两组均为1(四分位距1-1),校正比值比1.51(95%可信区间1.02至2.23),比值比>1的概率Pr(OR>1)=0.98;第28天WHO量表评分组间差异证据很少(1.02(0.55至1.87),Pr(OR>1)=0.53)。因预设无效规则提前终止,结论为无获益证据。
要点
- 住院covid-19患者(多为不需氧气的轻症)口服替米沙坦40 mg/天28天,第14天WHO量表评分中位数1(IQR 1-1)vs 对照组1(1-1),校正OR 1.51(95%CI 1.02-2.23),Pr(OR>1)=0.98。
- 第28天WHO量表评分组间差异证据很少:1.02(0.55-1.87),Pr(OR>1)=0.53。
- 试验因预设无效规则提前终止,作者结论为基于疾病严重度评分无获益证据。
- 入组为既往未用血管紧张素受体阻滞剂、实验室确诊SARS-CoV-2感染且住院治疗的成人;393例中388例(98.7%)用替米沙坦40 mg/天。
- 787例随机,778例(98.9%)来自印度,9例(1.1%)来自澳大利亚。
适用人群与场景
- 年龄至少18岁、既往未用血管紧张素受体阻滞剂、实验室确诊SARS-CoV-2感染且住院管理covid-19的患者。
- 试验在印度和澳大利亚17家医院开展;787例随机,778例(98.9%)来自印度,9例(1.1%)来自澳大利亚。
诊断标准与关键阈值
- 主要终点为第14天改良WHO临床进展量表(WHO scale)疾病严重度评分,在意向治疗人群中按有序量表分析。
处置流程与药物剂量
- 口服血管紧张素受体阻滞剂(印度为替米沙坦)或安慰剂,1:1随机,疗程28天。
- 替米沙坦40 mg/天:393例随机至血管紧张素受体阻滞剂组中388例(98.7%)使用替米沙坦40 mg/天。
研究设计与关键结果
- 研究设计:实用、适应性、多中心、3期随机对照试验(CLARITY),17家医院,787例随机(血管紧张素受体阻滞剂组393例,对照组394例)。
- 第14天WHO量表评分中位数:血管紧张素受体阻滞剂组1(四分位距1-1,n=384)vs 对照组1(1-1,n=382),校正比值比1.51(95%可信区间1.02至2.23),Pr(OR>1)=0.98。
- 第28天WHO量表评分组间差异证据很少:1.02(0.55至1.87),Pr(OR>1)=0.53。
- 试验因预设无效规则提前终止;结论为基于疾病严重度评分无获益证据,使用主要为替米沙坦40 mg/天。
- 筛查时间2020年5月3日至2021年11月13日,筛查2930例。
证据类型、等级与局限
- 证据类型:实用、适应性、多中心、3期随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于住院covid-19患者(多为不需氧气的轻症),使用替米沙坦40 mg/天未显示基于疾病严重度评分的获益,不能据此推荐使用血管紧张素受体阻滞剂。
- 试验因预设无效规则提前终止,作者结论为无获益证据;原文未据此给出推荐。
指南或共识出处
- CLARITY试验,注册号ClinicalTrials.gov NCT04394117。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine whether disrupting the renin angiotensin system with angiotensin receptor blockers will improve clinical outcomes in people with covid-19.
DESIGN: CLARITY was a pragmatic, adaptive, multicentre, phase 3, randomised controlled trial.
SETTING: 17 hospital sites in India and Australia.
PARTICIPANTS: Participants were at least 18 years old, previously untreated with angiotensin receptor blockers, with a laboratory confirmed diagnosis of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection who had been admitted to hospital for management of covid-19.
INTERVENTION: Oral angiotensin receptor blockers (telmisartan in India) or placebo (1:1) for 28 days.
MAIN OUTCOME MEASURES: The primary endpoint was covid-19 disease severity using a modified World Health Organization Clinical Progression Scale (WHO scale) at day 14. Secondary outcomes were WHO scale scores at day 28, mortality, intensive care unit admission, and respiratory failure. Analyses were evaluated on an ordinal scale in the intention-to-treat population.
RESULTS: Between 3 May 2020 and 13 November 2021, 2930 people were screened for eligibility, with 393 randomly assigned to angiotensin receptor blockers (of which 388 (98.7%) to telmisartan 40 mg/day) and 394 to the control group. 787 participants were randomised: 778 (98.9%) from India and nine (1.1%) from Australia. The median WHO scale score at day 14 was 1 (interquartile range 1-1) in 384 participants assigned angiotensin receptor blockers and 1 (1-1) in 382 participants assigned placebo (adjusted odds ratio 1.51 (95% credible interval 1.02 to 2.23), probability of an odds ratio of >1 (Pr(OR>1)=0.98). WHO scale scores at day 28 showed little evidence of difference between groups (1.02 (0.55 to 1.87), Pr(OR>1)=0.53). The trial was stopped when a prespecified futility rule was met.
CONCLUSIONS: In patients admitted to hospital for covid-19, mostly with mild disease, not requiring oxygen, no evidence of benefit, based on disease severity score, was found for treatment with angiotensin receptor blockers, using predominantly 40 mg/day of telmisartan.
TRIAL REGISTRATION: ClinicalTrials.gov NCT04394117.
参考来源
- Jardine MJ, Kotwal SS, Bassi A, et al. Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. BMJ. 2022. PMID: 36384746. doi:10.1136/bmj-2022-072175
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。